Skip to main content
. 2020 Dec 23;23(6):894–904. doi: 10.1093/neuonc/noaa285

Fig. 3.

Fig. 3

A) Forest plot of pooled incidence rate (patient-years) for HR+/HER2− MBC. Random effects model presented. Incidence per year of follow-up ranged from 0.03–0.10. Median follow-up times ranged from 32.0–42.8 months. B) Funnel plot for publication bias according to studies reporting brain metastasis in HR+/HER2− MBC. HER2−, hormone receptor negative; HR+, hormone receptor; MBC, metastatic breast cancer.